An open label study to assess the safety and efficacy of COR-003 (2S 4R-Ketoconazole) in the treatment of Endogenous Cushing's syndrome
ID Number 14-0895Principal Investigator(s)
Eliza B Geer
Department(s) or Division(s)
Endocrinology, Diabetes and Bone Disease
The purpose of this clinical research study is to test the effects of this experimental new drug COR-003 on people with Cushing's syndrome by measuring the cortisol levels in the urine and to see if there is any harm caused when using COR-003.
Recruiting Patients: No